Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

CSL Ltd

CSL:ASX

CSL Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)273.30
  • Today's Change-5.15 / -1.85%
  • Shares traded726.77k
  • 1 Year change-10.60%
  • Beta0.4654
Data delayed at least 20 minutes, as of Apr 26 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
Select bar for recommendation details.
Recommendations18-Apr-24
Buy3
Outperform8
Hold4
Underperform1
Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for CSL Ltd have a median target of 307.92, with a high estimate of 333.34 and a low estimate of 227.87. The median estimate represents a 12.67% increase from the last price of 273.30.
High22.0%333.34
Med12.7%307.92
Low-16.6%227.87

Dividends in USD

In 2023, CSL Ltd reported a dividend of 2.42 USD, which represents a 10.20% increase over last year. The 15 analysts covering the company expect dividends of 2.66 USD for the upcoming fiscal year, an increase of 9.83%.
Div growth (TTM)10.20%
More ▼

Earnings history & estimates in USD

CSL Ltd reported annual 2023 earnings of 4.53 per share on Aug 14, 2023.
Average growth rate+2.15%
More ▼

Revenue history & estimates in USD

CSL Limited had revenues for the full year 2023 of 13.31bn. This was 26.02% above the prior year's results.
Average growth rate+12.07%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.